Bosutinib is under clinical development by Pfizer and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bosutinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bosutinib (Bosulif) a aminoquinoline derivative, acts as anti-neoplastic agent. It is formulated as film coated tablets for oral route of administration. Bosulif is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy, and as first line treatment of chronic myelogenous leukemia (CML).
The drug candidate is under development for the treatment of pediatric patients with newly diagnosed chronic phase Ph+ CML, HER2- breast cancer, chronic myelogenous leukemia as a third line therapy in Japan, mild cognitive impairment due to degenerative dementia, relapsed or refractory acute lymphocytic leukemia and amyotrophic lateral sclerosis. It was also under development for the treatment of HER2 Positive breast cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma and polycystic kidney disease and recurrent glioblastoma (GBM).
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Bosutinib’s drug-specific PTSR and LoA scores, buy the report here.